HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Harvey I. Pass Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pass, H. I. Articles by Matthews, W. J. Search for Related Content PubMed PubMed Citation Articles by Pass, H. I. Articles by Matthews, W. J. Related Collections Related Article

Ann Thorac Surg 1995;59:835-844
© 1995 The Society of Thoracic Surgeons

Characteristics of Nine Newly Derived Mesothelioma Cell Lines

Surgery Branch, Thoracic Oncology Section; Naval Medical Oncology Branch; Pediatric Tumor Biology-Ultrastructural Pathology Section and Cytopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

This report characterizes nine new cell lines derived from patients with malignant pleural mesothelioma. The lines were initiated between July 1990 and July 1992 from solid tumors (5 lines) or effusions (4 lines) and had proliferated for a period of at least 2 months without senescence. They were characterized by cell size, doubling time, immunohistochemical analyses, electron microscopy, and chromosomal karyotyping. Growth factor/cytokine elaboration was determined using enzyme-linked immunoassays. The established lines were similar in morphology to their parent tumor (ie, epithelial or sarcomatoid). Cell sizes ranged from 59 to 81 µm, and the doubling times varied from 31 to 65 hours. The lines stained with cytokeratin and showed expected negative staining for adenomarkers including B72.3 and carcinoembryonic antigen. All cell lines exhibited aneuploidy, with modal chromosome numbers between 40 and 81 and had multiple chromosomal aberrations. Significant production of granulocyte--monocyte colony-stimulating factor, leukemia inhibitory factor, platelet-derived growth factor, and interleukin-6 was seen. These new cell lines derived from human mesotheliomas can now be used to aid in the design of innovative treatment strategies.

Related Article

DISCUSSION
Ann. Thorac. Surg. 1995 59: 844. [Extract] [Full Text]

This article has been cited by other articles:

				A. V. Ivanova, C. M.V. Goparaju, S. V. Ivanov, D. Nonaka, C. Cruz, A. Beck, F. Lonardo, A. Wali, and H. I. Pass Protumorigenic Role of HAPLN1 and Its IgV Domain in Malignant Pleural Mesothelioma Clin. Cancer Res., April 15, 2009; 15(8): 2602 - 2611. [Abstract] [Full Text] [PDF]

				I. Graziani, S. Eliasz, M. A. De Marco, Y. Chen, H. I. Pass, R. M. De May, P. R. Strack, L. Miele, and M. Bocchetta Opposite Effects of Notch-1 and Notch-2 on Mesothelioma Cell Survival under Hypoxia Are Exerted through the Akt Pathway Cancer Res., December 1, 2008; 68(23): 9678 - 9685. [Abstract] [Full Text] [PDF]

				T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]

				M. Stapelberg, N. Gellert, E. Swettenham, M. Tomasetti, P. K. Witting, A. Procopio, and J. Neuzil {alpha}-Tocopheryl Succinate Inhibits Malignant Mesothelioma by Disrupting the Fibroblast Growth Factor Autocrine Loop: MECHANISM AND THE ROLE OF OXIDATIVE STRESS J. Biol. Chem., July 8, 2005; 280(27): 25369 - 25376. [Abstract] [Full Text] [PDF]

				C. D. Hoang, X. Zhang, P. D. Scott, T. J. Guillaume, M. A. Maddaus, D. Yee, and R. A. Kratzke Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells: Association with Distinct Malignant Phenotypes Cancer Res., October 15, 2004; 64(20): 7479 - 7485. [Abstract] [Full Text] [PDF]

				C. D. Hoang, J. D'Cunha, M. G. Kratzke, C. E. Casmey, S. P. Frizelle, M. A. Maddaus, and R. A. Kratzke Gene Expression Profiling Identifies Matriptase Overexpression in Malignant Mesothelioma Chest, May 1, 2004; 125(5): 1843 - 1852. [Abstract] [Full Text] [PDF]

				P. A. Janne, M. L. Taffaro, R. Salgia, and B. E. Johnson Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma Cancer Res., September 15, 2002; 62(18): 5242 - 5247. [Abstract] [Full Text] [PDF]

				S. Toyooka, H. I. Pass, N. Shivapurkar, Y. Fukuyama, R. Maruyama, K. O. Toyooka, M. Gilcrease, A. Farinas, J. D. Minna, and A. F. Gazdar Aberrant Methylation and Simian Virus 40 Tag Sequences in Malignant Mesothelioma Cancer Res., August 1, 2001; 61(15): 5727 - 5730. [Abstract] [Full Text] [PDF]

				S. C. Grondin and D. J. Sugarbaker Pleuropneumonectomy in the Treatment of Malignant Pleural Mesothelioma* Chest, December 1, 1999; 116 (2009): 450S - 454S. [Abstract] [Full Text] [PDF]

				H. I. Pass, B. W. Robinson, J. R. Testa, and M. Carbone Emerging Translational Therapies for Mesothelioma* Chest, December 1, 1999; 116 (2009): 455S - 460S. [Abstract] [Full Text] [PDF]

				J. B. RUBINS, T. GREATENS, R. A. KRATZKE, A. T. TAN, V. A. POLUNOVSKY, and P. BITTERMAN Lovastatin Induces Apoptosis in Malignant Mesothelioma Cells Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1616 - 1622. [Abstract] [Full Text]